Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 267 results

The plausibility battleground at the EPO

EU09-11-2020Markus Grammel

Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

A stricter interpretation: the EPO and antibodies

EU27-10-2020Joachim Wachenfeld and Florian Grasser

Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

Why Santen ends Neurim-style SPCs

EU25-08-2020Robert Stephen and Gareth Morgan

In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.

How patents for transgenic mice got caught in a sufficiency trap

16-07-2020David Fyfield

As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.

EPO’s G3/19: no turning back?

Germany02-07-2020Anna Gregson

The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

UK25-06-2020Sarah Morgan

Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers. 

SPCs: a deep dive into CJEU case law

23-06-2020Katie Cambrook and Ben Millson

The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Royalty Pharma: welcome clarity mixed with unwelcome ambiguity

EU15-05-2020Beatriz San Martin

The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.

Why things could get ugly over COVID-19 patents

30-04-2020Mark Engelman

Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.

Showing 1 to 10 of 267 results

LSIPR